Shots:

• Sabin to get an exclusive technology license for all three vaccine candidates i.e- Ebola Zaire- Ebola Sudan and Marburg vaccines and patent rights related to vaccines
• In 2013- GSK acquired three vaccines from the US NIH & Okairos. The candidates are based on GSK’s ChAd3 platform and were developed by GSK including P-II development of Ebola Zaire vaccine
• Additionally- Sabin has collaborated with VRC at NIAID to advance ChAd3 Ebola and Marburg vaccines and has evaluated them in multiple trials in 5-000+ adults & 600+ children which demonstrated high immunogenicity among the population  

Click here to­ read full press release/ article |

Ref: GSK | Image: GSK